Nkarta: at least as good as Fate, at a tenth of the price

In the battle of Car-NK therapy companies Nkarta today looks to have at least matched Fate Therapeutics. The big difference for investors will be where expectations had settled: before today’s market open Nkarta was worth just $250m, less than a tenth of Fate’s valuation.